NDA 022372 · Azurity
Suprep Bowel Prep Kit
Magnesium Sulfate, Potassium Sulfate, Sodium Sulfate · Oral
OrphanLast checked: Nov 19, 2026Latest source record: Nov 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Aug 5, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 0 recruiting
FAERS reports
4,386
628 serious, 31 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
SUPREP Bowel Prep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older. SUPREP Bowel Prep Kit is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adult and pediatric patients 12 years of age and older. ( 1 )
Mechanism: Sulfate salts provide sulfate anions, which are poorly absorbed. The osmotic effect of unabsorbed sulfate anions and the associated cations causes water to be retained within the gastrointestinal tract.
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 5, 2020 Supplement 13 · Efficacy LabelLetter
- Aug 5, 2010 Original approval · Type 4 - New Combination LabelReviewSummary Review
1 products under this application
- SUPREP BOWEL PREP KIT · MAGNESIUM SULFATE 1.6GM/BOT; POTASSIUM SULFATE 3.13GM/BOT; SODIUM SULFATE 17.5GM/BOT · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Suprep Bowel Prep Kit" as an intervention, any sponsor and status, largest first.
- BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult SubjectsPivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT01786629 · 338 participants · Start Dec 2012 · Primary completion May 2013
Drug: SUPREP Bowel Prep Kit; FDA approved bowel preparation containing electrolytes · For: Colonoscopy; Bowel Preparation; Endoscopy
Sites: Mobile, Alabama; Anaheim, California; Indianapolis, Indiana · 10 sites in all
- Pilot Study to Assess Tolerability and Feasibility of Oral Sulfate Solution (SUPREP) in Hospitalized PatientsPivotal-lookingStatus unknown
University of VirginiaAcademic, hospital or other
NCT04504292 · 124 participants (planned) · Start Aug 1, 2020 · Primary completion May 30, 2021
Drug: SUPREP Bowel Prep Kit; Golytely Oral Product · For: Inpatient Colonoscopy; Oral Sulfate Solution; Polyethelene Glycol
MercyOne Des Moines Medical CenterAcademic, hospital or other
NCT02523911 · 0 participants · Start Mar 2016 · Primary completion Dec 2017
Drug: Simethicone; Placebo and 1 more · For: Colorectal Cancer
Sites: Jacksonville, Florida; Clive, Iowa
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting1,648
- nausea1,151
- abdominal distension394
- drug ineffective381
- abdominal pain377
- headache374
- dizziness228
- abdominal pain upper194
- wrong technique in product usage process170
- tremor162
- retching150
- abdominal discomfort135
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 19 |
| 2015 | 55 |
| 2016 | 520 |
| 2017 | 619 |
| 2018 | 677 |
| 2019 | 598 |
| 2020 | 523 |
| 2021 | 557 |
| 2022 | 339 |
| 2023 | 190 |
| 2024 | 121 |
| 2025 | 103 |
| 2026 | 59 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.